This experience is more common than many people realize, and it points to an important distinction in how ketamine can be used. The infusion itself is a powerful neurological event, but it’s not the only thing ketamine has to offer. When ketamine is paired with structured therapeutic work, the approach becomes something different: ketamine-assisted psychotherapy, a model designed to use the brain’s temporary state of heightened receptivity as an active opportunity for psychological change. Here’s what KAP is, how it differs from standalone infusions, who each approach fits, and what the process looks like in practice.
Depending on how ketamine is administered and what surrounds the treatment, it can serve two very different purposes in mental health care.
The first role is purely pharmacological. In a standalone infusion protocol, ketamine is used primarily to reduce acute psychiatric symptoms, most often in treatment-resistant depression. The goal is rapid stabilization: reducing suicidal ideation, lifting depressive episodes, or breaking a mood cycle that hasn’t responded to conventional medications. On its own, this is a legitimate and often life-changing intervention.
The second role is therapeutic in a broader sense. In ketamine-assisted psychotherapy, the altered state ketamine produces is used intentionally as a context for psychological work. Rather than simply resting through the experience and going home, the patient works with a trained therapist before, during, and after the session to process emotions, examine entrenched thought patterns, and turn insights into lasting change.
The underlying neuroscience explains why this distinction matters clinically. Ketamine acts as an NMDA receptor antagonist, and its antidepressant effects are thought to involve a rapid increase in synaptic plasticity, including the release of BDNF (brain-derived neurotrophic factor) and activation of AMPA receptors. Together these create what researchers and clinicians often describe as a neuroplasticity window: a period when the brain may be more open to forming new neural connections and, by extension, more receptive to new ways of thinking, feeling, and responding.
That’s the scientific rationale behind pairing ketamine with psychotherapy. If the brain is temporarily more malleable, the question becomes: what do we do with that window? A standalone infusion lets it open and close. Ketamine-assisted psychotherapy uses it purposefully. Neither approach is inherently superior for every person, but the goals, structure, and intended outcomes of each are different, and understanding that difference is the first step toward knowing which path fits you.
Ketamine-assisted psychotherapy, often called KAP therapy, is a structured clinical model in which a trained therapist is actively involved at every stage. It’s a coordinated protocol built around three phases, not simply an infusion with a therapist in the room.
Before any ketamine is administered, the patient and therapist meet for preparation sessions. These conversations establish therapeutic rapport, which matters because the ketamine experience can bring up unexpected emotions and memories. They also give the patient room to set clear intentions: what they hope to explore, release, or understand more deeply. Preparation goes beyond logistics. It’s where the therapeutic relationship is built and where the patient learns to approach the altered state with openness rather than resistance. Many clinicians consider this phase foundational, because the quality of the preparation often shapes the quality of the experience itself.
During the ketamine session, the patient reclines comfortably, often wearing eye shades and listening to carefully selected music. The therapist stays present throughout, not directing the experience, but offering a grounded, supportive presence. This is a real departure from the standalone infusion model, where the patient rests without a therapist present.
The therapist’s role is to hold space, offer gentle guidance if needed, and observe the patient’s emotional and somatic responses. The altered state can allow patients to access difficult material, including memories, emotions, or psychological patterns, with less of the defensive reactivity that usually makes that material hard to approach in conventional therapy.
This is where ketamine integration therapy comes in, and many clinicians consider it the most important part of the entire model. Integration is the post-session work in which the patient and therapist process what emerged during the dosing experience: vivid imagery, unexpected emotions, insights about relationships or self-concept, or a felt sense of connection that’s hard to articulate right away.
Without integration, these experiences can feel fleeting or confusing. With it, they become material for real psychological change. Integration sessions help patients translate what happened during the altered state into concrete shifts in how they think, behave, and relate to themselves and others. That follow-through separates a temporary shift from a lasting one, and it’s what makes KAP a fundamentally different treatment model than infusions administered in isolation.
Standalone ketamine infusions are typically administered in a medical setting, often as a series of six infusions over two to three weeks. The patient rests comfortably while the ketamine is delivered intravenously, and the primary goal is symptom reduction, particularly for people with treatment-resistant depression who haven’t found relief through antidepressants.
This approach is medically sound and can produce real results. For patients in acute crisis, the rapid antidepressant effect of ketamine infusions can be stabilizing within hours of the first session. That speed and reliability is one of the infusion model’s most important clinical advantages.
What the standard protocol doesn’t include is structured psychological support during or after the session. The neuroplasticity window opens, the patient experiences the altered state, and then they go home. Without therapeutic guidance, the insights or emotional shifts that arise during the infusion may fade before they’re processed or applied to daily life. The brain was temporarily more open to change, but nothing actively used that openness.
A useful way to frame it: standalone infusions reset the brain’s chemistry, while ketamine-assisted psychotherapy uses that reset period as an active opportunity for therapeutic change. Both are valid, but they’re designed for different outcomes.
None of this means infusions without therapy are ineffective. For many patients, symptom reduction alone is a necessary outcome, especially as a first step. But for people whose depression is entangled with unresolved trauma, deeply ingrained thought patterns, or a history of psychological complexity, infusions alone may address the surface without reaching the underlying structure. KAP is designed to go deeper, using the same pharmacological mechanism as a doorway into fuller psychological work.
This difference also helps explain why some people get lasting relief from infusions while others find the effects wear off. The treatment itself may not have failed. The integration process may simply not have been in place to support what the brain was ready to do.
Choosing between the two isn’t about one being better than the other. It’s about matching the approach to your clinical picture, readiness, and goals.
Strong candidates for KAP tend to be people whose depression is accompanied by unresolved trauma, PTSD, or entrenched psychological patterns that haven’t shifted through talk therapy alone. For them, the altered state can make it possible to approach difficult memories with reduced emotional reactivity, engaging material that has historically felt too overwhelming to face directly, with the therapeutic structure to do that work safely. People with co-occurring PTSD and depression are a particularly relevant group: symptom reduction alone may not be enough if the underlying trauma stays unaddressed.
Standalone infusions may suit patients in acute crisis who need rapid stabilization before they’re emotionally ready for therapeutic work. If someone is in a severe depressive episode with heavy functional impairment or suicidal ideation, the immediate priority is symptom relief, and asking that person to do deep psychological exploration during the altered state may not be appropriate at that stage. Some people also simply want symptom reduction as their primary goal, without a desire or clinical need for psychological exploration, and for them infusions may be entirely sufficient.
The approaches aren’t mutually exclusive, either. Many patients begin with a standalone infusion series for stabilization and later transition into KAP or integration therapy as their condition improves. This sequential path is often the most thoughtful one, because it meets the patient where they are at each stage of recovery rather than applying a single model regardless of readiness.
Ketamine’s antidepressant mechanism is one of the better-understood aspects of its clinical use. NMDA receptor antagonism triggers downstream effects, including BDNF release and AMPA receptor activation, that support rapid synaptic plasticity. This is why ketamine can produce antidepressant effects within hours rather than the weeks conventional medications require. The neuroplasticity window is real, measurable in preclinical research, and forms the scientific foundation of the KAP model.
KAP itself is a newer clinical model than standalone infusions, and the research base is still developing. Early clinical evidence and practitioner experience point to real benefits, particularly for patients with treatment-resistant depression and co-occurring trauma. The field draws on frameworks from psychedelic-assisted therapy research, including psilocybin work at institutions like Johns Hopkins and NYU, and applies similar principles to ketamine. The evidence is promising and growing, and best practices continue to evolve.
SPRAVATO (esketamine), the FDA-cleared nasal spray form of ketamine, already builds structured oversight into its protocol: patients receive it in a certified healthcare setting and remain under observation for two hours after each dose. That monitoring exists primarily for safety, but it reflects a broader clinical principle, that ketamine-based treatment benefits from structured support rather than isolated administration. KAP extends the principle into the psychological domain.
Clinicians who practice KAP generally describe integration as the variable most likely to determine if the neuroplasticity window translates into lasting change. That squares with the broader psychotherapy literature, which consistently shows that insight without application rarely produces durable outcomes.
Asking the right questions before you begin helps you evaluate a provider’s approach and the odds that the treatment structure will support the outcomes you want. Bring these to any consultation: Is a therapist involved before, during, and after the ketamine sessions? What does the integration process look like, and how many integration sessions are included? How many dosing sessions are in the protocol, and at what intervals? What happens if the experience brings up difficult emotions or memories? How does the team coordinate care if you’re also working with a separate psychiatrist or therapist?
A thorough psychiatric evaluation is the first step regardless of which approach you’re considering. It establishes your diagnosis and treatment history, determines which model fits your situation, and surfaces any contraindications before treatment begins.
Approach this as a collaborative conversation. The best outcomes in ketamine treatment come from individualized planning that accounts for who you are, what you’ve already tried, and what you’re ready to engage with. A good provider won’t push you toward a particular model before understanding your history. And if you’re not sure which questions to ask or how to weigh the answers, that’s normal. This is a complex, evolving area of treatment, and working through it is exactly what a qualified clinical team is there for.
Standalone infusions address the brain’s chemistry directly, producing rapid symptom relief through a well-understood neurological mechanism. Ketamine-assisted psychotherapy uses that same mechanism as a doorway into deeper psychological work, pairing the brain’s temporary receptivity with structured therapeutic support. For many people, especially those carrying unresolved trauma or entrenched patterns alongside their depression, that combination offers something infusions alone can’t.
At Delray Brain Science, we offer a range of ketamine-based services, including medically supervised infusions and SPRAVATO treatment, alongside psychiatric evaluation and full care planning built for lasting recovery. If you’re weighing KAP, standalone infusions, or a combined approach, schedule a consultation with our team and we’ll help you find the approach that gives your treatment the best foundation.
